EcoR1 Capital’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

EcoR1 Capital’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-175,000	Closed	-$2.09M	–	73
2022 Q3	$2.09M	Hold	175,000	–	–	0.06%	59
2022 Q2	$2.21M	Hold	175,000	–	–	0.08%	58
2022 Q1	$1.97M	Hold	175,000	–	–	0.06%	66
2021 Q4	$3.1M	Hold	175,000	–	–	0.1%	54
2021 Q3	$4.03M	Buy	175,000 +150,000	+600%	+$3.27M	0.14%	45
2021 Q2	$582K	Hold	25,000	–	–	0.02%	69
2021 Q1	$779K	Hold	25,000	–	–	0.03%	65
2020 Q4	$995K	Buy	+25,000	New	+$1M	0.05%	63

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

EcoR1 Capital's KNTE Position: Q4 2022 in Review

EcoR1 Capital sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 175,000 shares — an estimated $2.09M sold.

EcoR1 Capital first reported a position in KNTE in Q4 2020 and held it in 8 quarters. The position peaked at $4.03M in Q3 2021. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

EcoR1 Capital reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
EcoR1 Capital sold 175,000 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $2.09M.
EcoR1 Capital first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
EcoR1 Capital's Kinnate Biopharma Inc. Common Stock position peaked at $4.03M in Q3 2021.
79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.